Article Sidebar
Published:
May 29, 2022Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Clinical efficacy and inflammatory factors in knee osteoarthritis with glucosamine hydrochloride plus meloxicam
Abstract
Purpose: To evaluate the efficacy and change in serum levels of inflammatory factors in knee osteoarthritis (KOA) treated with glucosamine hydrochloride plus meloxicam.
Methods: In total, 114 patients with KOA who received glucosamine hydrochloride plus meloxicam treatment were included in the study and equally distributed to a control group and a study group. The control group received glucosamine hydrochloride, and the study group received a similar treatment but, received in additional, meloxicam. Clinical efficacy, numerical rating scale (NRS) score, quality of life (QoL) score, index of severity for osteoarthritis (ISOA) score, and related inflammatory factors were assessed and compared.
Results: The study group outperformed the control group in terms of clinical efficacy. Significantly lower NRS scores were obtained in the study group at T2, T3, and T4 than those of the control group (p < 0.001). Before treatment, the two groups presented similar ISOA score, QoL score, and interleukin (IL)- 6 and tumor necrosis factor- α (TNF-α) levels. After treatment, ISOA score, and IL-6 and TNF-α levels declined in all patients, with lower results obtained in the study group. All patients obtained significantly higher Qol score after treatment, with higher outcomes observed in the study group.
Conclusion: The combination of glucosamine hydrochloride and meloxicam effectively improves the joint function of patients with KOA and relieves symptoms such as joint swelling and pain. Hus, t treatment strategy has great promise.
